These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 24876182)

  • 1. Pharmacological treatment of neuropsychiatric symptoms in Alzheimer's disease: a systematic review and meta-analysis.
    Wang J; Yu JT; Wang HF; Meng XF; Wang C; Tan CC; Tan L
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):101-9. PubMed ID: 24876182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence.
    Sink KM; Holden KF; Yaffe K
    JAMA; 2005 Feb; 293(5):596-608. PubMed ID: 15687315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The value of cholinesterase inhibitors for improving neuropsychiatric and functional assessment scores in patients with Alzheimer disease: a systematic review and meta-analysis of on placebo-controlled RCTs.
    Zhang Y; Sun Y; Hu X; Yao Y; Wang J
    Int J Surg; 2024 Jun; 110(6):3937-3945. PubMed ID: 38573101
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A double-blind randomized placebo-controlled withdrawal trial comparing memantine and antipsychotics for the long-term treatment of function and neuropsychiatric symptoms in people with Alzheimer's disease (MAIN-AD).
    Ballard C; Thomas A; Gerry S; Yu LM; Aarsland D; Merritt C; Corbett A; Davison C; Sharma N; Khan Z; Creese B; Loughlin P; Bannister C; Burns A; Win SN; Walker Z;
    J Am Med Dir Assoc; 2015 Apr; 16(4):316-22. PubMed ID: 25523285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis.
    Kishi T; Matsunaga S; Oya K; Nomura I; Ikuta T; Iwata N
    J Alzheimers Dis; 2017; 60(2):401-425. PubMed ID: 28922160
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of cholinesterase inhibitors on behavioural disturbances in Alzheimer's disease: a systematic review.
    Grimmer T; Kurz A
    Drugs Aging; 2006; 23(12):957-67. PubMed ID: 17154660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Atypical antipsychotics for psychosis in adolescents.
    Kumar A; Datta SS; Wright SD; Furtado VA; Russell PS
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD009582. PubMed ID: 24129841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
    Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
    Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of psychotropic medications in relation to neuropsychiatric symptoms, cognition and functional performance in Alzheimer's disease over a three-year period: Kuopio ALSOVA study.
    Törmälehto S; Martikainen J; Bell JS; Hallikainen I; Koivisto AM
    Int Psychogeriatr; 2017 Oct; 29(10):1723-1733. PubMed ID: 28625207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
    Rodda J; Morgan S; Walker Z
    Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of Antidepressants for Depression in Alzheimer's Disease: Systematic Review and Meta-Analysis.
    Orgeta V; Tabet N; Nilforooshan R; Howard R
    J Alzheimers Dis; 2017; 58(3):725-733. PubMed ID: 28505970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
    Jiang D; Yang X; Li M; Wang Y; Wang Y
    J Neural Transm (Vienna); 2015 Aug; 122(8):1157-66. PubMed ID: 25547862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
    Ballard C; Waite J
    Cochrane Database Syst Rev; 2006 Jan; 2006(1):CD003476. PubMed ID: 16437455
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychiatric symptoms of dementia: are pharmacological treatments effective and safe?
    Ford AH
    J Neurol Neurosurg Psychiatry; 2015 Jan; 86(1):4. PubMed ID: 24876187
    [No Abstract]   [Full Text] [Related]  

  • 15. Innovations: geriatric psychiatry: diagnosis and treatment of neuropsychiatric symptoms in Alzheimer's disease.
    Lavretsky H; Nguyen LH
    Psychiatr Serv; 2006 May; 57(5):617-9. PubMed ID: 16675752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential effects of current specific treatments on behavioral and psychological symptoms in patients with Alzheimer's disease: a 12-month, randomized, open-label trial.
    Cumbo E; Ligori LD
    J Alzheimers Dis; 2014; 39(3):477-85. PubMed ID: 24164733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Memantine monotherapy for Alzheimer's disease: a systematic review and meta-analysis.
    Matsunaga S; Kishi T; Iwata N
    PLoS One; 2015; 10(4):e0123289. PubMed ID: 25860130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time to Treatment Initiation in People With Alzheimer Disease: A Meta-Analysis of Randomized Controlled Trials.
    Tsoi KK; Hirai HW; Chan JY; Kwok TC
    J Am Med Dir Assoc; 2016 Jan; 17(1):24-30. PubMed ID: 26392193
    [TBL] [Abstract][Full Text] [Related]  

  • 20. To treat or not to treat? A meta-analysis of the use of cholinesterase inhibitors in mild cognitive impairment for delaying progression to Alzheimer's disease.
    Diniz BS; Pinto JA; Gonzaga ML; Guimarães FM; Gattaz WF; Forlenza OV
    Eur Arch Psychiatry Clin Neurosci; 2009 Jun; 259(4):248-56. PubMed ID: 19224111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.